check_circleStudy Completed
Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Bayer Identifier:
14792
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Regulatory Post Marketing Surveillance Study on Nexavar®
Trial purpose
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
Key Participants Requirements
Sex
BothAge
20 - 91 YearsTrial summary
Enrollment Goal
2845Trial Dates
September 2009 - August 2015Phase
N/ACould I Receive a placebo
NoProducts
Nexavar (Sorafenib, BAY43-9006)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Korea, Republic Of |
Primary Outcome
- Adverse events collectiondate_rangeTime Frame:From start of treatment to 4 weeks after discontinuation of treatmentenhanced_encryptionYesSafety Issue:
Secondary Outcome
- Duration of treatment, dosage and indicationdate_rangeTime Frame:Whole treatment periodenhanced_encryptionNoSafety Issue:
- Tumor statusdate_rangeTime Frame:Whole treatment periodenhanced_encryptionNoSafety Issue:
- Performance statusdate_rangeTime Frame:Whole treatment periodenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A